top of page

In the Press

Being part of a Biotechnology Startup means we operate in a fast-paced world where changes happen often and quickly. This media section includes all the exciting news and updates about WINCAL BIOPHARM, INC., as well as industry news and analysis. If you have any questions about our articles, please get in touch today.

 

At 2024 ARVO conference (Seattle, WA), WincalBio gave an oral presentation that the OPC screening platform enabled the delivery of the anti-VEGF treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye drops. In a laser-induced choroid neovascularization (CNV) mouse model, the OPC eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, showing similar efficacy to the intravitreal (IVT) injections. This breakthrough received huge interest and enthusiasm from the meeting participants. Other therapeutic antibodies can be similarly delivered within the eyes using Wincal's proprietary Ocular Penetration Carrier (OPC) screening platform, as shown by animal studies. This innovation allows patients to administer treatment conveniently at home using eye drops, which suggests that non-invasive eye drops could potentially replace traditional intravitreal injection methods for treating eye diseases.

 

*The OPC screening platform was developed to identify antibody-carrier complexes capable of delivering therapeutic agents into the back of the eye, such as the vitreous, retina, and choroid, without relying on needle injections. The key to this technology is finding a matching carrier to each antibody to facilitate drug delivery inside the eye.

bottom of page